Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor-related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors

Lillian L. Siu, Neeltje Steeghs, Tarek Meniawy, Markus Joerger, Jennifer L. Spratlin, Sylvie Rottey, Adnan Nagrial, Adam Cooper, Roland Meier, Xiaowei Guan, Penny Phillips, Gaurav Bajaj, Jochem Gokemeijer, Alan J. Korman, Kyaw Lwin Aung, Matteo S. Carlino

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Number of pages6
JournalJournal of Clinical Oncology
Volume35
DOIs
Publication statusPublished - 20 May 2017

Cite this

Siu, L. L., Steeghs, N., Meniawy, T., Joerger, M., Spratlin, J. L., Rottey, S., Nagrial, A., Cooper, A., Meier, R., Guan, X., Phillips, P., Bajaj, G., Gokemeijer, J., Korman, A. J., Aung, K. L., & Carlino, M. S. (2017). Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor-related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors. Journal of Clinical Oncology, 35. https://doi.org/10.1200/JCO.2017.35.15_suppl.104